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 Abstract (< 250 words) 
 
Introduction: The diagnosis of sports-related concussion is mainly based on subjective clinical 
symptoms and neuropsychological tests. Thus, reliable brain injury biomarkers to assess when it is 
safe to return to play are highly desirable. The overall objective of this study was to evaluate the 
utility of two newly described tau fragments for diagnosis and prognosis of sports-related concussions  
 
Materials and Methods: This multicenter prospective cohort study involved all 12 teams of the top 
professional ice hockey league in Sweden. A total of 288 players consented to participate in the study. 
Thirty-five players sustained concussions, of whom 28 underwent repeated blood samplings at 1, 12, 
36, and 144 hours after the trauma, or when the player returned to play (7- > 90 days).  
 
Results: There was no significant increase in the levels of tau-A in post-concussion samples 
compared with preseason values. However, serum levels of tau-C were significantly higher in post-
concussion samples compared with preseason. Further, levels of Tau-A correlated with the duration 
of post-concussive symptoms. 
 
Discussion: Tau-A in serum, which is newly discovered biomarker, could be used to predict when it 




Concussion is common in contact sports such as ice hockey, American football, boxing and rugby. 
The term concussion or mild traumatic brain injury (mTBI) is used interchangeably in the medical 
literature. Concussion is characterized by a complex pathophysiology affecting normal brain 
function following exposure to excessive forces to the head (McCrory et al. 2013). Following this 
are short-lived neurological impairments, with symptoms such as headaches, dizziness and memory 
complaints. The majority of concussions resolve within 7-10 days (McCrory et al. 2013;McCrea et 
al. 2003;Makdissi et al. 2010) but in 10-15 % of the affected individuals, the symptoms persist for 
more than 10 days following injury (McCrory et al. 2013).  
 
The standard management of sports-related concussion consists of immediate removal of players 
from active competition and evaluation by the team physician. Cognitive and physical rest is then 
recommended until the player is asymptomatic (McCrory et al. 2013;Petraglia et al. 2012). Today, 
due to the lack of reliable objective tools, both the diagnosis of sports-related concussion and the 
decision to return to play are based on the resolution of subjective symptoms. Thus, there is a great 
need to develop objective tools to diagnose and monitor concussion.  
 
Several studies have evaluated biomarkers of neuronal and astroglial injury in serum of individuals 
(including athletes) with mild traumatic brain injury (Zetterberg et al. 2009), (Graham et al. 2011), 
Mannix et al. 2014). Recently, using a novel ultra-sensitive method to measure tau in plasma we 
found increased levels of plasma total-tau in concussed professional ice hockey players, where the 
levels correlated with the resolution of post-concussive symptoms and the players returning to play 
(Shahim et al. 2014).  
 
Fragmentation of tau protein as a function of neuronal injury has been described in several papers 
(Rissman et al. 2004;Knoblach et al. 2002;Behl 2000). Recently, tau protein cleaved by ADAM10 
measured in serum correlated with dementia symptoms in a Alzheimer disease (AD) patients 
(Henriksen et al. 2013). Another potential biomarker for neurological injury is the caspase-3 
generated fragment of tau called tau-C, which reflect neuronal apoptosis (Rissman et al. 
2004;Knoblach et al. 2002;Behl 2000).  Recently tau-C was shown to be elevated in serum of AD 
patients (Henriksen et al. 2014). In this study, we tested the specific hypothesis that concussion 




Study design and study population 
Serum samples were acquired from an on-going prospective multicenter cohort study of concussion 
among professional ice hockey players from the Swedish Hockey League (Shahim et al JAM N 
2014). The study was approved by the Ethics Committee for Medical Research at the University of 
Gothenburg, Sweden, and the Swedish Hockey League. Written informed consent was obtained 
from all 288 study participants comprised of 24 players from each of the 12 teams. The teams’ 
physicians were present during all season games and documented all signs and symptoms of 
concussion and recorded the date when the player had completely recovered from his concussion 
and was able to return to unrestricted competition. The diagnosis of concussion was based on the 
latest diagnostic guidelines (Barr and McCrea 2001;McCrea et al. 2003). The teams’ physicians 
received injury protocol, the Rivermead Post-concussion Symptoms Questionnaire (Cifu et al. 
2014), instructions for blood sampling, standardized blood sampling equipment, and instructions for 
the handling of the blood samples for the local laboratory. Prior to start of the season, all players 
were examined physically and with the Standardized Assessment of Concussion (Barr and McCrea 
2001;McCrea et al. 2003). Players from two of the contesting teams were sampled for baseline 
values prior to the start of the season (n=47). In addition one of these teams were also sampled 
prior, 1 hour and 12 hours after a friendly game without incidents of concussion. In players who 
sustained head injury or concussion during the season, consecutive blood samples were collected at 
1 hour, 12 hours, 36 hours, and 144 hours after the injury. Players with postconcussive symptoms 
longer than on the 6 days were sampled on the morning of the day when the player was considered 
ready to return to play. 
 
Biochemical procedure 
Blood samples were collected by venipuncture into gel-separator tubes and centrifuged within 20-
60 minutes. Samples were aliquoted and stored at -80°C for later analysis.  
The neo-epitope fragments of tau degradation were assessed by solid phase competitive enzyme 
linked immunosorbent assays (ELISAs). Each neo-epitope constitutes a specific amino acid 
sequence that has been generated by enzymatic cleavage. The assays used throughout this study are 
based on mouse monoclonal antibodies and are specific for caspase-3 and ADAM10-generated neo-
epitope fragments of Tau protein, and the Tau-A assay has previously been described in detail 
elsewhere.15 The antibodies only react specifically with the cleaved protein and not with intact (full-
length) Tau protein, and therefore only detect Tau protein fragments.  
Samples were assayed for the content of Tau-A and Tau-C using the lower limit of quantification 
determined to 11.9 ng/mL and 10.4 ng/mL, respectively. If measured values fall below the LLOQ, 
the LLOQ value was assigned to the sample measurement. In brief both assays are competitive 
ELISA assays. The Tau-A assay detects a neoepitope identified by LC-MS/MS as the amino acid 
sequence TPRGAAPPGQ and the Tau-C assay detects the caspase-3 generated cleavage site of Tau 
at Asp421 (Henriksen et al. 2013;Henriksen et al. 2014).  
Statistical analysis 
We conducted non-parametric analyses as the data was positively skewed. Data are presented as 
median ± interquartile range (IQR). For the group comparison of post-concussion samples versus all 
preseason values (paired data not available), the Mann-Whitney U test was used. For multiple group 
comparisons, the Kruskal-Wallis test was used. Linear regression analysis was conducted to 
examine whether the biomarker levels at 1 hour post-concussion could predict return to play. The 
area under the receiver operating characteristic curve was calculated to determine the diagnostic 
accuracy of the biomarkers. Statistical significance was determined at p < 0.05. All statistical 
analyses were performed using GraphPad Prism version 6.0 (GraphPad Inc., San Diego, CA).   
Results 
 
Of a total of 288 ice hockey players, 35 sustained sports-related concussion between September 13, 
2012 and January 31, 2013, of whom 28 consented to participate in the study. The remaining 
concussed players either declined to participate, or had uncertain diagnosis of concussion. Three of 
the included players were unconscious and 25 did not lose consciousness but experienced 
symptoms such as headache, confusion, dizziness or nausea. The majority of the players were free 
of symptoms within 10 days after concussion (n=22), while 6 players had post-concussive 
symptoms longer than10 days.  
 
There were no significant changes (p=0.90) between the serum levels of Tau-A after concussion (all 
time point) versus preseason samples (Figure 1A). However, the levels of Tau-C were significantly 
(p=0.03) increased in postconcussion samples compared with preseason samples (Figure 1B). 
 
When players were followed longitudinally, the levels of Tau-A peaked at 12 hours postconcussion, 
,however the increase was not statistically significant from the levels at 1 hour, 12 hours, 36 hours 
144 hours or when the players returned to play, as well as compared to the preseason values (Figure 
2A). Similar to Tau-A, the levels of Tau-C remained unchanged over time (Figure 2B). 
 
Severity of concussion 
As most concussion symptoms resolve within a week, we graded the severity of concussion based 
on the resolution of post-concussive symptom and player returning to play: 1) those who were 
symptom-free and hade safe return to play within 10 days, and 2) those who required return to play 
more than 10 days. Serum Tau-A levels at 1 hour and 12 hour post-concussion were significantly 
elevated in players with persistent post-concussive symptoms lasting longer than 10 days compared 
to players with symptoms resolving within 10 days (Figure 3A). In contrast to Tau-A, the levels of 
Tau-C did not differ between the players with post-concussive symptoms lasting longer than 10 
days versus players with symptoms resolving withing10 days (Figure 3B). Furthermore, serum Tau-
A concentrations 1 hour and 12 hours after concussion correlated with the number of days it took 
for players to return to play (Figure 3D). However, serum Tau-C concentrations at 1 hour and 12 
hours after concussion did not significantly relate to the resolution of post-concussive symptoms 
(Figure 3D). We also tested if there was any correlation between the levels of tau fragments and 
total-tau (T-tau) previously measured in the same cohort of ice hockey players (Shahim et al, JAMA 
N 2014). As shown in Figure 3E, the mean serum Tau-A levels at 1-12 hours post-concussion were 
linearly related to plasma T-tau levels assessed 1-12 hours post-concussion. The relationship 
between serum Tau-A and T-tau was less strong when either marker was sampled at other time 
points after concussion (data not shown). In contrast to Tau-A, there was no relationship between 
Tau-C levels and T-tau (Figure 3E). 
 
Diagnostic accuracy of the biomarkers 
To determine whether Tau-A and Tau-C could discriminate between players with late and early 
return to play, we calculated the area under the receiver operating curve (AUC). The AUC for Tau-
A at 12h (AUC = 0.91; 95% CI, 0.78-1, p = 0.005) was greater than at 1 hour post-concussion 
(AUC = 0.87; 95% CI, 0.71-1, p = 0.01). Tau-C was unable to discriminate between early and late 
return to play at both 1 hour and 12 hours post-concussion (p = 0.55 and 0.50, respectively) (Figure 
5).   
 
Discussion 
The major findings of this study were that serum Tau-A concentrations at 1 and 12 hours could 
predict the number of days it took for the players to return to play and serum Tau-A levels at 1 hour 
and 12 hours after concussion could discriminate between early and late return to play.  
 
This is the first study to measure tau fragments in serum from concussed professional athletes. 
Similar to the previously reported study where we measured plasma total-tau (T-tau)  (Shahim et al. 
2014) in the same cohort of individuals, serum Tau-A correlated with the number of days it took to 
return to play. In addition, there is a linear relationship between Tau-A and T-tau. In contrast to T-
tau, which can only be measured using the ultra-sensitive single molecular array technique (Shahim 
et al. 2014), tau fragments are measured using standard ELISA. One plausible explanation which 
allows quantification of tau fragments in serum are that the may easily cross the blood-brain barrier, 
(Wang et al. 2012).  
 
Knowing which players are at increased risk of long-term post-concussive symptoms could be of 
great value in the management of sports-related concussion.  Serum levels of  Tau-A measured at 1 
hour and 12 hours post-concussion could identify these cases of high risk players, which should be 
managed with a higher degree of vigilance by personal specially trained (McCrory et al. 2013). 
Interestingly, Tau-A provides a graded response in players with post-concussive symptoms lasting 
longer than 10 days with the greatest diagnostic accuracy (AUC = 0.91) being at 12 hours after 
concussion. Although based on a limited number of measurements, an interesting finding in this 
study is that the return to play values of the biomarker did significantly drop, when compared to the 
earlier post-concussion values . This could indicate that despite the players are declared fit to return 
to play, the underlying damage may still be present. 
 
Considering the significant separation of players with short-term from the players with persistent 
post-concussive symptoms it was surprising that no separation between preseason and post-
concussion levels was observed for serum Tau-A. However, this is potentially explained by the 
large variation in post-concussion levels due to the mixture of severities of concussions. Further 
analysis of this finding using paired pre-season and post-concussion samples are of great interest. 
However, Tau-C could separate between preseason and post-concussion levels. The reason for this 
presently is unclear, but it is appealing to assume Tau-C being related to a milder component of the 
injury than Tau-A. 
 
The main limitation of this study was the relative small sample size, which restricts the possibilities 
of examining biomarker levels in relation to different forms and severities of concussion. Further, 
we did not have access to preseason samples for all ice hockey players, which would have made it 
easier to evaluate the comparison between post-concussion versus preseason baseline values. 
Finally, although measuring axonal injury by Tau-A is an important aspect of determining the 
severity of concussion, concussion is a heterogeneous disorder affecting all cell types in the brain 
(Zetterberg et al. 2013), therefore a panel of biomarkers reflecting not only cortical damage  but 
also astrocytic, endothelial, and microglial injury may be required in the clinical management of 
athletes with  sports-related concussion. 
 
In conclusion, measurement of Tau-A separates ice hockey players with short-term post-concussive 
symptoms from those with prolonged symptoms and hence this marker, pending further validation, 
could serve as a helpful tool in deciding if and when a player is fit for return to play. 
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 Players with RTP > 10 days have significantly higher levels (*) of Tau-A at both 1h and 12h post-
concussion compared to players with RTP ≤ 10 days and furthermore the levels are significantly 
higher than preseason levels. Players with RTP ≤ 10 days did not have significantly elevated levels 
of Tau-A compared to preseason. Boxes represent median and bars interquartile range. 




















RTP > 10 
(n=5) 
Age, y  27.5 (19-40) 25.5 (20-34) 27.5 (19-38) 25.5 (20-34) 











Tau-C, ng/mL 17.6 
(11.1-
46.8) 







Figure 1. Preseason and Postconcussion Levels of Tau-fragment 
 
 
There were no significant changes between the serum levels of Tau-A after concussion (all time) 
versus preseason samples. However, serum Tau-C was significantly higher in postconcussion 




Figure 2. Longitudinal biomarker changes 
A) Median levels of Tau-A peaked at 12 hours after concussion, but were not significantly different 
from all other time points. B) Concentrations of Tau-C remained unchanged over time. RTP 
indicates return to play. 
 
 
Figure 3. Biomarker concentration in relation to early versus late resolution of post-
concussion symptoms 
Players who had RTP > 10 days have significantly higher levels of Tau-A both 1 h and 12 h after 
concussion compared with players who returned to play within 10 days as well as preseason values. 
However, in players who RTP within 10 days, the levels of both Tau-A were not significantly 
elevated compared with preseason values. The levels of Tau-C did not differ significantly between 
different concussion categories. 
  












(A)Tau-A and (B) Tau-C concentrations after 1 hour and 12 hours postconcussion are shown in 
relation to resolution of post-concussive symptoms and return to play. One player resigned due to 
persistent post-concussive symptoms and was entered more than 90 days in the graph. The mean 
serum Tau-A concentration at 1 and 12 hours postconcussion is linearly related to the plasma tau 
concentration measured at 1 and 12 hour (C). For measures of either Tau-A or Tau-C and tau at all 
other  time points the correlation between the two markers is less strong (data not shown) 
 
Figure 5. Diagnostic accuracy of the biomarkers 
 
Area under the receiver operating characteristic curve (AUC) for Tau-A and Tau-C at both 1 hours 
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